PMID- 25039799
OWN - NLM
STAT- MEDLINE
DCOM- 20151021
LR  - 20161125
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 94
IP  - 2
DP  - 2015 Feb
TI  - Impact of self-administration of romiplostim by patients with chronic immune 
      thrombocytopenia compared with administration by a healthcare provider.
PG  - 169-76
LID - 10.1111/ejh.12415 [doi]
AB  - OBJECTIVE: This post hoc analysis evaluated romiplostim self-administration (SA 
      group) vs. romiplostim administration by a healthcare provider in a clinical 
      setting (HCP group) in patients with chronic immune thrombocytopenia (ITP). 
      METHODS: Outcomes from 3 ITP trials allowing self-administration in patients 
      achieving a stable romiplostim dose for >/=3 consecutive weeks were compared. 
      Evaluations were conducted for 12-wk treatment intervals. Efficacy endpoints 
      included percentage of patients and weeks with platelets within the target range 
      of 50-200 x 10(9) /L and safety. RESULTS: Baseline characteristics suggested less 
      severe disease in the SA groups (n = 563) than in the HCP groups (n = 241). The 
      SA groups had greater proportions of patients achieving the target platelet range 
      (55-58% vs. 40-52%) and greater proportions of weeks with a platelet response 
      (75-88% vs. 47-76%) than the HCP groups. The rate of romiplostim discontinuation 
      was twofold to fivefold lower in the SA groups than in the HCP groups. Rates of 
      duration-adjusted adverse events (AEs), serious AEs and treatment-related AEs 
      were also lower in the SA groups. CONCLUSIONS: In conclusion, in adults with ITP 
      receiving romiplostim, self-administration was comparable to healthcare provider 
      administration in terms of efficacy and safety profiles, suggesting that 
      self-administration of romiplostim is a feasible option for certain patients with 
      ITP.
CI  - (c) 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Selleslag, Dominik
AU  - Selleslag D
AD  - AZ Sint-Jan, Brugge-Oostende, Belgium.
FAU - Bird, Robert
AU  - Bird R
FAU - Altomare, Ivy
AU  - Altomare I
FAU - Giagounidis, Aristoteles
AU  - Giagounidis A
FAU - Janssens, Ann
AU  - Janssens A
FAU - Pabinger, Ingrid
AU  - Pabinger I
FAU - Pullarkat, Vinod
AU  - Pullarkat V
FAU - Wei, Helen
AU  - Wei H
FAU - Kreuzbauer, Georg
AU  - Kreuzbauer G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140808
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Receptors, Fc)
RN  - 0 (Receptors, Thrombopoietin)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 9014-42-0 (Thrombopoietin)
RN  - GN5XU2DXKV (romiplostim)
SB  - IM
MH  - Chronic Disease
MH  - Clinical Trials, Phase III as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Purpura, Thrombocytopenic, Idiopathic/*drug therapy/surgery
MH  - Randomized Controlled Trials as Topic
MH  - Receptors, Fc/administration & dosage/*therapeutic use
MH  - Receptors, Thrombopoietin/agonists
MH  - Recombinant Fusion Proteins/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Self Administration
MH  - Thrombopoietin/administration & dosage/adverse effects/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - diagnosis
OT  - primary immune thrombocytopenia
OT  - romiplostim
OT  - self-administration
OT  - splenectomy
OT  - treatment
EDAT- 2014/07/22 06:00
MHDA- 2015/10/22 06:00
CRDT- 2014/07/22 06:00
PHST- 2014/07/09 00:00 [accepted]
PHST- 2014/07/22 06:00 [entrez]
PHST- 2014/07/22 06:00 [pubmed]
PHST- 2015/10/22 06:00 [medline]
AID - 10.1111/ejh.12415 [doi]
PST - ppublish
SO  - Eur J Haematol. 2015 Feb;94(2):169-76. doi: 10.1111/ejh.12415. Epub 2014 Aug 8.